Ambrx Biopharma Inc.

AMAMNYSEHealthcare

$28.00

+$0.02(+0.07%)

Market Cap$1.8B

P/E Ratio—

52W High$28.15

52W Low$6.55

Avg Volume2.0M

Open$27.99

Beta-2.36

Free Cash Flow Financials Revenue

Ambrx Biopharma Inc. (AMAM) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

AMAM · free cash flow · updated Jun 9, 2026

Core FCF metrics

AMAM · FCF · TTM · margin & CAGR

Free cash flow was −$69.7M for FY2022 (fiscal year ending 2022-12-31), down 45.7% year-over-year The FCF margin was -942.0%.

FY2022 Free Cash Flow−$69.7M▼ -45.7% YoY

Trailing 12M (TTM)−$58.8Mtrailing 4 quarters sum

FCF Margin-942.0%−$69.7M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

AMAM · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$68.7M(1M)−$69.7M▼ 45.7%-942.0%

FY2021−$44.6M(3M)−$47.8M▼ 129.7%-641.8%

FY2020−$20.6M(0M)−$20.8M▼ 640.4%-152.3%

FY2019−$2.8M(0M)−$2.8M—-27.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

AMAM · P/FCF · FCF yield · FCF per share

Ambrx Biopharma Inc. (AMAM) reported negative free cash flow of −$0.07B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-12-31

Cash flow statement summary

AMAM · cash flow statement · operating / investing / financing

For FY2022, Ambrx Biopharma Inc. generated −$68.7M in operating cash flow and spent 1M in capital expenditures, yielding −$69.7M in free cash flow.

Operating Activities

−$68.7M

Cash from core business operations

2022-12-31

Investing Activities

−$46.7M

CapEx, acquisitions & investments

2022-12-31

Financing Activities

+$0.9M

Buybacks, dividends & debt

2022-12-31

FCF FormulaOperating CF (−$68.7M) − |CapEx| (1M) = FCF (−$69.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

AMAM vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Ambrx Biopharma Inc.YOU

AMAM

−$69.7M-45.7%-942.0%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Ambrx Biopharma Inc. (AMAM) reported free cash flow of −$69.7M for FY2022 (fiscal year ending 2022-12-31), down 45.7% year-over-year. The FCF margin was -942.0%.

Ambrx Biopharma Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 4 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

AMAM free cash flow · 8 questions

Ambrx Biopharma Inc. free cash flow was −$69.7M for FY2022, down 45.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$58.8M.

AMAM free cash flowAMAM FCFAMAM FCF 2022AMAM free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Ambrx Biopharma Inc. · Ambrx Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026